Business Wire

SFL – First-Half 2018 Results

Share

Regulatory News:

Société Foncière Lyonnaise (Paris:FLY):

 

Rental income: €96.1 million (up 4.9% like-for-like)

EPRA earnings: €51.7 million (up 4.1%)

Attributable net profit: €200.2 million

Property portfolio value: €6,409 million (up 2.9%)

EPRA NNNAV: €82.3 per share (up 2.7% over 6 months / 12.0% over 1 year)

The interim consolidated financial statements for the six months ended 30 June 2018 were approved by the Board of Directors of Société Foncière Lyonnaise on 26 July 2018, at its meeting chaired by Juan José Brugera.

Business indicators were once again robust in the first half thanks to the high portfolio occupancy rate, while the period also saw further gains in the portfolio's appraisal value and the Company's net asset value.

The auditors have completed their review of the financial statements and issued their report on the interim financial information, which does not contain any qualifications or emphasis of matter.

Consolidated data (€ millions)
    H1 2018   H1 2017   Change
Rental income   96.1   98.6   -2.6%
Adjusted operating profit* 78.7 82.5 -4.6%
Attributable net profit 200.2 378.7 -
EPRA earnings   51.7   49.7   +4.1%
* Operating profit before disposal gains and losses and fair value adjustments
 
    30/06/2018   31/12/2017   Change
Attributable equity 3,857 3,763 +2.5%
Consolidated portfolio value excluding transfer costs 6,409 6,229 +2.9%
Consolidated portfolio value including transfer costs   6,811   6,619   +2.9%
EPRA NNNAV 3,830 3,729 +2.7%
EPRA NNNAV per share   €82.3   €80.1  

Results: robust business indicators

  • First-half consolidated rental income amounted to €96.1 million, down by a modest €2.6 million or 2.6% from the €98.6 million reported for the same period of 2017. Like-for-like growth went a long way towards offsetting the impact of selling the IN/OUT property in September 2017.
    • On a like-for-like basis (excluding all changes in the portfolio affecting period-on-period comparisons), rental income was €4.2 million (4.9%) higher, reflecting the impact of new leases signed in the second half of 2017 and the first half of 2018, mainly in the Washington Plaza, 103 Grenelle, Cézanne Saint-Honoré and 9 Percier properties, as well as an increase in rents for Galerie des Champs-Elysées retail units.
    • The sale of the IN/OUT building on 29 September 2017 led to a €6.5 million decrease in rental income compared to first-half 2017.
    • Lastly, income from assets under redevelopment and various penalties dipped by €0.3 million versus first-half 2017.
  • Operating profit before disposal gains and losses and fair value adjustments to investment property amounted to €78.7 million in first-half 2018 versus €82.5 million in the year-earlier period.
  • The portfolio’s appraisal value at 30 June 2018 was 2.9% higher on a like-for-like basis than at 31 December 2017. The increase led to the recognition of positive fair value adjustments to investment property of €159.2 million at 30 June 2018 versus positive adjustments of €382.6 million at 30 June 2017.
  • Net finance costs amounted to €16.5 million in first-half 2018 compared with €21.2 million in the year-earlier period. The period-on-period decrease of €4.6 million reflected the Group's lower average cost of debt and reduced debt burden, which led to a €6.2 million reduction in recurring financial expense.
  • After taking into account these core items, the Group reported attributable net profit for the period of €200.2 million, compared with €378.7 million in first-half 2017. EPRA earnings came to €51.7 million in first-half 2018 compared with €49.7 million in the year-earlier period, an increase of 4.1%.

First-half 2018 Business Review

Rental operations:

In a still favourable rental market in the Paris region, shaped by increased volumes compared to 2017 and higher rents, particularly in the capital’s Central Business District, during the first half of 2018 SFL signed leases on around 8,500 sq.m., located mainly in the Washington Plaza, Cézanne Saint-Honoré and Louvre Saint-Honoré complexes.

The new leases were signed at an average nominal rent of €686 per sq.m, corresponding to an effective rent of €603 per sq.m.

The physical occupancy rate for revenue-generating properties remained high, standing at 96.5% at 30 June 2018 compared with 96.4% at 31 December 2017. The remaining vacant units are located mainly in the Cézanne Saint-Honoré complex in Paris and the Le Vaisseau building in Issy-les-Moulineaux. The EPRA vacancy rate improved to 2.7% from 3.1% at 31 December 2017.

Development operations:

Properties undergoing development at 30 June 2018 represented roughly 15% of the total portfolio. They consist mainly of three flagship projects being implemented over the next four years, concerning:

  • the retail space in the Louvre Saint-Honoré complex,
  • the Emile Zola office complex acquired in 2017, which will be extensively remodelled based on the building permit obtained in May 2018,
  • the 96 Iéna building, for which the planning appeal process has now ended, allowing renovation work to begin next January.

Capitalized work carried out in first-half 2018 totalled €13.6 million and concerned the above three redevelopment projects, as well as work to improve common areas and the services offered by the Group’s properties in response to the new needs expressed by tenants and users on the back of emerging office use practices.

Portfolio operations:

No properties were purchased or sold during first-half 2018.

Financing

In May 2018, SFL issued €500 million worth of seven-year bonds maturing on 29 May 2025 and paying an annual coupon of 1.50% (see press release dated 17 May 2018). The proceeds will be used for general corporate purposes. The issue, at a historically low interest rate, extends the average maturity of the Group’s debt, as part of its proactive balance sheet management strategy.

Net debt at 30 June 2018 amounted to €1,699 million, compared with €1,631 million at 31 December 2017, representing a loan-to-value ratio of 24.9%. At 30 June 2018, the average cost of debt after hedging was 1.8% and the average maturity was 4.8 years.

At the same date, SFL had €820 million in undrawn lines of credit.

Net Asset Value

The consolidated market value of the portfolio rose by 2.9% to €6,409 million excluding transfer costs at 30 June 2018, from €6,229 million at 31 December 2017. The increase reflected higher rental values, resilient prime property yields in Paris and the value added by the Group to properties undergoing redevelopment.

The average EPRA topped-up net initial yield (NIY) was 3.2% at 30 June 2018, unchanged from 31 December 2017.

EPRA NNNAV stood at €3,830 million or €82.3 per share at 30 June 2018 versus €80.1 per share at 31 December 2017, reflecting increases of 2.7% over the past six months and 12.0% over twelve months.

Board of Directors

The Board of Directors noted Anne-Marie de Chalambert’s decision to resign from her position as a director and extended its warmest thanks to her for her valuable contribution to the Board’s work since she was first elected in 2010.

During the same meeting, the Board appointed Arielle Malard de Rothschild as an independent director, subject to ratification at the Company's next General Meeting.

Alternative Performance Indicators (APIs)

API EPRA earnings:

       
€ millions   H1 2018   H1 2017
Attributable net profit 200.2   378.7
Less:
Profit (loss) on asset disposals - -
Fair value adjustments to investment property (159.2) (382.6)
Fair value adjustments to financial instruments, discounting adjustments to debt and related costs 1.5 0.0
Tax on the above items 2.0 20.1
Non-controlling interests in the above items   7.2   33.5
EPRA earnings   51.7   49.7

API EPRA NNNAV:

       
€ millions   30/06/2018   31/12/2017
Attributable equity 3,857   3,763
Treasury shares 10 11
Unrealised capital gains 20 17
Fair value adjustments to fixed rate debt   (57)   (62)
EPRA NNNAV   3,830   3,729

API Net debt:

       
€ millions   30/06/2018   31/12/2017
Long-term borrowings and derivative instruments 1,798   1,661
Short-term borrowings and other interest-bearing debt   13   36
Debt in the consolidated statement of financial position   1,811   1,697
Less:
Current account advances (liabilities) (56) (56)
Accrued interest, deferred recognition of debt arranging fees, negative fair value adjustments to financial instruments (2) 6
Cash and cash equivalents   (54)   (16)
Net debt   1,699   1,631

More information is available at www.fonciere-lyonnaise.com

About SFL

Leader in the prime segment of the Parisian commercial real estate market, Société Foncière Lyonnaise stands out for the quality of its property portfolio, which is valued at €6.4 billion and is focused on the Central Business District of Paris (#cloud.paris, Edouard VII, Washington Plaza, etc.), and for the quality of its client portfolio, which is composed of prestigious companies in the consulting, media, digital, luxury, finance and insurance sectors. As France’s oldest property company, SFL demonstrates year after year an unwavering commitment to its strategy focused on creating a high value in use for users and, ultimately, substantial appraisal values for its properties.

Stock market: Euronext Paris Compartment A – Euronext Paris ISIN FR0000033409 – Bloomberg: FLY FP – Reuters: FLYP PA

S&P rating: BBB+ stable outlook

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

SFL
Thomas Fareng, +33 (0)1 42 97 27 00
t.fareng@fonciere-lyonnaise.com
www.fonciere-lyonnaise.com
or
Evidence
Grégoire Silly, 06 99 10 78 99
gregoire.silly@evidenceparis.fr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KAYTUS Unveils Upgraded MotusAI to Accelerate LLM Deployment12.6.2025 14:11:00 EEST | Press release

KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, today announced the release of the latest version of its MotusAI AI DevOps Platform at ISC High Performance 2025. The upgraded MotusAI platform delivers significant enhancements in large model inference performance and offers broad compatibility with multiple open-source tools covering the full lifecycle of large models. Engineered for unified and dynamic resource scheduling, it dramatically improves resource utilization and operational efficiency in large-scale AI model development and deployment. This latest release of MotusAI is set to further accelerate AI adoption and fuel business innovation across key sectors such as education, finance, energy, automotive, and manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612546292/en/ MotusAI Dashboard As large AI models become increasingly embedded in real-world applications, enterprises are

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 202512.6.2025 14:00:00 EEST | Press release

Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefi

Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event12.6.2025 14:00:00 EEST | Press release

As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern. Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains. “We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s coming next,” said Andrew Busch, economic futurist and economist at AndrewBusch.com. “Tariffs are no longer just a policy lever; they’re a strategic force reshaping the g

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce the company’s strategic vision to redefine the standard of care for B-cell malignancies. “The data presented at EHA 2025 underscore the strength of BeOne’s comprehensive hematology pipeline, built on the success of BRUKINSA, the only BTK inhibitor to demonstrate superior progression-free survival over ibrutinib in a Phase 3 trial,1” said Lai Wang, Ph.D. Global Head of R&D at BeOne. “With our potentially best-in-class BCL2 inhibitor, sonrotoclax, and fi

Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 11:17:00 EEST | Press release

Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involvement in the IPCEI-CIS project, along with partnerships with Deutsche Telekom AG, NVIDIA, Telefónica, a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye